Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Abstract: An in vitro assay for inducing extracellular trap (ET) formation, including contacting immune cells, in in vitro culture or within a biological sample, with immobilized human polyvalent immunoglobulins; and to uses thereof, in particular in an in vitro method for screening a drug for its ability to modulate ET formation, in an in vitro method for assessing the susceptibility of a subject to ET formation, in an in vitro method for predicting the response of a subject to a modulator of ET formation, and in in vitro method for monitoring the response of a subject to an immunomodulator.

Abstract: The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.

Abstract: An apparatus for simulating an atonic uterine body after childbirth includes a one-piece part, which includes: a flexible body having the shape of an atonic uterine body after childbirth, the flexible body is bendable by hand so that the flexible body reproduces a haptic behavior of an atonic uterine body after childbirth; and a rigid neck extending the flexible body, the rigid neck surrounding an opening of the part, the rigid neck having a rigidity greater than a rigidity of the flexible body. The part defines an outer surface and an inner surface. The inner surface defines an inner cavity of the part, wherein the inner cavity opens out into the outer surface so as to define the opening.

Abstract: The invention relates to a method of processing data representative of a person’s binocular motricity, the method comprising the following steps: stimulating the binocular motricity of a person by means of a binocular motricity stimulation device (21) configured to specifically stimulate saccades, vergences or a combination of both or of a reading test (22); physical stimuli in 3D real space seen with both eyes naturally (without artifices); acquiring the movement of the right eye (RE) and the left eye (LE) of a person (P) during said stimulation and, if applicable, a stimulation signal from the binocular motor stimulation device; the method comprising the following steps implemented in a processing unit (3); determination from the movement of the left eye (LE) and the right eye (RE), of an effective trajectory (Tr1) of the eyes in response to each stimulation, an effective trajectory corresponding to a saccade and/or a vergence movement of the eyes.

Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

Abstract: The inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to a method of treating a subject suffering from a cancer comprising a step of administration simultaneously, separately or sequentially to said subject a therapeutically amount of i) a population of derived engineered fetal stem cells carrying cancer associated fetal neo-antigen and ii) a compound selected from a group which activates immune response, as a combined preparation.

Abstract: The present invention relates to methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof. In particular, the present invention relates to a method for performing antisense oligonucleotide-mediated exon skipping in a retina cell of a subject comprising the step of injecting into the vitreous of the subject an amount of the antisense oligonucleotide.

Abstract: A topical composition including erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the composition is topically administered. The composition may further include a penetration enhancer. The treated subject may be younger than three years old. Also, woven or non-woven fabric support including erlotinib and to dressings, patches, gloves and socks having the support useful in the treatment of a PPK.

Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Abstract: A method of preparation of a gold electrode, which includes the steps of: a) inkjet printing on a substrate an ink including gold nanoparticles functionalized with a compound Cap of formula (I) HS-A-Polyalkylene glycol (I), wherein A is a bound or an alkyl chain having 1 to 12 carbon atoms and wherein polyalkylene glycol is polyethylene glycol, polypropylene glycol or a mixture thereof; and b) annealing printed ink, wherein the compound Cap has an average molar mass of less than 500 g/mol, preferably an average molar mass of about 200 g/mol. Also, an electrode obtainable by the method of the invention, a sensor including the electrode and the use of the sensor.

Abstract: A method is provided for manipulating objects in a cavity including a liquid, the method including providing in at least one region of the cavity objects capable of absorbing light in a given wavelength range, forming an aggregate of the objects by submitting them to an acoustic field, and disrupting the aggregate by submitting the aggregate to a light beam emitting at the given wavelength range. Also provided is a device for manipulating objects.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Abstract: A method for constructing a high-resolution merged signal from low-resolution signals acquired by an acquisition device includes acquisition of low-resolution signals (BR), measurement and/or estimation of acquisition parameters, pre-merging of the signals as a function of the low-resolution signals and of the parameters, filtering of the pre-merged signal, transmission of the filtered pre-merged signal and of the parameters, calculation of an estimate of the pre-merged signal by an inverse filtering of the filtered pre-merged signal, and determination, according to a variational method, of the high-resolution merged signal from the estimate of the pre-merged signal and of the parameters, a resolution of the merged signal is greater than a resolution of each signal.

Abstract: The present invention aims at improving the Doppler imaging of a biological sample comprising blood. For this, it is proposed a method for imaging a biological sample (10), the sample (10) comprising blood (14) comprising diffusors and solid tissue (16), the method comprising obtaining observation, each observation being characterized by a different point spread function associating a signal to each location of the region of interest, the signal comprising a first contribution representative of the diffusors of blood vessels within the location, a second contribution representative of the tissue diffusors and a third contribution representative of blood signal associated to blood diffusors outside of the location, and estimating, for each location, the blood flow by using a statistical analysis.

Abstract: The present invention relates to a compound of the following formula (I). The invention also relates to uses thereof as a chromophore as such or for building pigments displaying special optical effects, including metal-like reflection.

Abstract: A concentration sensor for at least one biological species in the blood includes a support, at least one waveguide, and an optomechanical resonator suspended from the support. The optomechanical resonator is optically coupled to the waveguide, and the optomechanical resonator is configured to vibrate in volume mode and includes at least one face extending in the plane of the sensor and configured to receive molecules of the given species. At least the face includes a functionalisation layer specific to the species, the optomechanical resonator having a smaller dimension in a direction normal to the plane of the sensor compared with the dimensions of the said face.

Abstract: Disclosed are methods for diagnosing CAT1-related diseases, wherein the methods include detecting CAT1 in a cell by a BLV.RBD ligand, or a variant or a fragment thereof. Also disclosed is a BLV.RBD ligand, or a variant or a fragment thereof for use in the treatment of CAT1-related diseases and/or BLV infections.

Abstract: The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.

Abstract: A 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of sickle cell disease in a patient in need thereof. Also, a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention and/or treatment of acute chest syndrome (ACS) in a sickle cell disease patient in need thereof.